Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus

Sponsor
Damanhour University
Study ID
NCT04240171
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 5Mg Tab — DRUG
    Dapagliflozin 5mg tablets daily
  • Glimepiride 4Mg Tab — DRUG
    Glimepiride Tablets daily

Study Details

Research objectives: The aim of the study to check the effect of Dapagliflozin versus Glimepiride on insulin regulated aminopeptidase (IRAPe), NT-Pro BNP and interleukin-34 (IL-34) in patients with type 2 diabetes mellitus, and associated it with insulin resistance.

Key Dates

Start date
Dec 1, 2020
Status verified
Apr 2023
Primary completion
Jan 30, 2022
Completion
Jan 31, 2022

Study Design

Enrollment
60 participants (actual)

Arms

  • Arm: dapagliflozin
    Group 1(n=30): are the patients who are prescribed dapagliflozin to control their blood sugar level.
  • Arm: glimepiride
    Group 2 (n=30): are the patients who are prescribed glimepiride

Primary Outcome Measure

Blood Sugar (mg/dl) [ Time Frame: three months ]

Related Studies